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ABSTRACT 
INTRODUCTION: Prostate cancer is the second most commonly diagnosed cancer in 
men. Robot Assisted Laparoscopic Prostatectomy (RALP) and External Beam Radiation 
Therapy (EBRT) are standard treatments for clinically localized prostate cancer, but 
both of these treatments have negative consequences for urinary and sexual function in 
patients. 
PURPOSE: To compare changes in urinary and sexual function for men treated with 
RALP and EBRT. 
HYPOTHESIS: It was hypothesized that patients treated with EBRT would have better 
recovery of sexual function, and patients treated with RALP would have better 
recovery of urinary function.  
METHODS: Urinary and sexual function for patients treated for prostate cancer was 
examined using Expanded Prostate Index Composite (EPIC) questionnaires. These 
questionnaires were completed before treatment and two years after initial treatment 
in 32 men treated with EBRT, and 104 men treated with RALP. The difference between 
initial treatment scores and 2-year scores were analyzed with a general linear 
model(GLM) procedure to assess the quality of life outcomes for EBRT and RALP. 
RESULTS: No significant difference was found for change in urinary function for either 
treatment group (p = 0.41).  EBRT was found to significantly increase recovery sexual 
function compared to RALP (p = 0.04).  
CONCLUSION: EBRT is a superior treatment for preserving sexual function in men with 
prostate cancer, whereas there is no significant difference in recovery of urinary 
function. 
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Fig 1.  Anatomy of the Prostate  (1) Ureter, (2) 
Vas Deferens, (3) Bladder, (4) Seminal Vesicle 
(5) Prostate (6) Urethra from Martin Allums; 
2017 
Fig 2. Neurovascular Bundles of the 
Prostate from Martin Allums; 2017 
OVERVIEW OF PROSTATE CANCER ANATOMY AND PHYSIOLOGY OF THE 
PROSTATE  
The prostate is a male specific organ that 
encircles the urethra and borders the inferior 
aspect of the bladder (see fig.1). The prostate 
contains the ejaculatory duct, which is the end of 
the spermatic tube that extends all the way down 
from the testes. Sperm travel through this tube to 
arrive at the urethra during ejaculation. Nerves 
that supply the urethra and penis run posterior-
laterally along the prostate and are contained in 
the neurovascular bundles (see fig. 2). The 
function of the prostate is to create and secrete 
certain components found in semen. One of these 
components is prostate specific antigen (PSA), 
which is a protein that helps maintain a low 
viscosity in semen to allow the sperm to swim 
freely (Lee et al. 436).  
Prostate Cancer 
Prostate cancer is the second most frequently 
diagnosed cancer in the United States, falling only 
behind skin cancer (Haas et al. 1). In a healthy 
functioning prostate the PSA that is produced is 
almost entirely secreted into the urethra during 
ejaculation, with only small levels leaking into 
bloodstream circulation (Stenman et al. 1). When 
prostate cells become cancerous they rapidly 
proliferate and create an excess amount of PSA. This 
is more PSA than can be secreted into the urethra 
during ejaculation, and the excess is leaked into 
circulation and that be detected by a blood tests and 
indicate abnormal prostatic tissue growth (Smith et 
al. 29). Thus, PSA screenings are conducted by 
physicians in men over fifty to look for sharp 
increases in PSA that could indicate prostate cancer 
(Smith et al. 29).  
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While elevated PSA levels may indicate a cancer, 
there are other conditions that can cause PSA levels 
to rise. Benign Prostatic Hyperplasia (BPH) is a 
common condition among men over the age of fifty 
which can also results in elevated levels of PSA 
(Stenman et al. 1). BPH is a condition where the 
prostate grows larger without evidence of 
malignancy (Stenman et al. 1). This additional 
growth of prostate cells will also produce an excess 
of PSA, which will be detected in a blood test. Other 
conditions such as a bladder or prostate infection 
can also cause the PSA to spike. If no inflammation 
or infection of the prostate is clinically apparent, 
then further evaluation of elevated PSA includes 
Transrectal Ultrasound (TRUS) guided biopsy of the 
prostate to deduce if prostate cells have become 
cancerous (Heidenreich et al. 70).  
A Transrectal Ultrasound (TRUS) guided biopsy takes up to twelve samples of prostatic tissue 
in each region of the prostate to test for malignancy (see fig. 3). The samples taken from the 
TRUS biopsy are examined and given a Gleason Score. The Gleason Score represents the 
number of cancerous cells within a sample and their histological appearance in an assigned 
grade from 1–5 (Humphrey 293). A grade of one represents cells that are packed closely together 
but are still separated with a uniform appearance and well differentiated growth patterns. A 
grade of five represents the most altered appearance of the cells with large, observable, different 
shaped masses (Humphrey 293). The grades 2–4 represent the range of appearances of the 
cancer cells between the grades 1 and 5 (Humphrey 293). The Gleason Score is calculated by 
summing the two largest grades assigned to the histological sample of the prostate tissue, 
generating a value of 2–10 (Humphrey 293). Patients with a Gleason Score of 2–6 are 
candidates for active surveillance, essentially close surveillance of PSA progression without 
definitive treatment to avoid over-treatment (Shah 1810). Patients with a Gleason Score of seven 
or greater are in need of definitive therapy (Shah 1810).   
Another tool used to assess the extent of the cancer is the Tumor-Node-Metastasis (TNM) 
staging system. The TNM cancer staging system is used to assign a stage to cancerous prostatic 
samples (Edge et al. 1471). The TNM outlines the location of the cancer in relation to the 
prostate gland and the rest of the body. The T in the score denotes a tumor in the prostate, the N 
signifies a tumor in a lymph node, and the M indicates metastasis in other locations in the body. 
A common score is T2a, which indicates a tumor involving one half a prostatic lobe or less. The 
TNM staging can be diagnosed from a TRUS biopsy, or by palpation of the prostate via rectal 
exam (Edge et al. 1417).  
Fig 3. Transrectal Ultrasound Guided Biopsy 
Specimen Sites from Martin Allums; 2017 
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Fig 4. Surgical Incision Sites for RALP 
from Martin Allums; 2017 
Treatment of Prostate Cancer 
Definitive Treatment Options 
Surgical removal of the prostate is a common 
procedure used to treat prostate cancer. The surgical 
techniques of prostatectomies have evolved in the last 
two decades from the traditional Radical Retropubic 
Prostatectomy (RRP) which was considered the standard 
of care for treatment of prostate cancer (Coelho et al. 
2003). A RRP is an invasive procedure which involves a 
large open incision in the abdomen and surgical 
dissection of the prostate (Barré 72). New surgical 
techniques have developed such that laparoscopic 
dissection (a minimally invasive procedure with a few 
small incisions) of the prostate can be achieved with the 
assistance of a da Vinci Robotic Surgical System. This 
new technology allows surgeons to perform a Robot 
Assisted Laparoscopic Prostatectomy (RALP) with 
minimal invasion compared to the open incision of the 
RRP (see fig. 4). RALP operations can be performed as 
Nerve Sparing (NS) procedures, where the neurovascular 
bundles are dissected away from the prostate in an attempt to preserve the urinary and sexual 
function of the patient (Coelho et al. 2006). As there is a neurovascular bundle that runs on both 
sides of the prostate, a NS procedure can be bilateral, where both neurovascular bundles are 
dissected away, or unilateral, if only one is dissected away. The type of NS procedure depends on 
the girth and location of the tumor. If the tumor extends into the regions of these neurovascular 
bundles, the neurovascular bundles will not be dissected away in an attempt to remove all 
cancerous cells (Talcott et al. 1117). 
External Beam Radiation Therapy is another common treatment for prostate cancer. EBRT is 
radiation delivered from an external source directed at the prostate from different angles to 
preserve the tissue around the prostate (Heidenreich et al. 72). If a patient has received a 
prostatectomy as initial treatment and there is reoccurrence of prostate cancer, they can go on to 
receive EBRT (Heidenreich et al. 76). However, once a patient receives EBRT for their initial 
treatment, they have received a lifetime dose of radiation to that area and are not able to receive 
additional radiation treatment for their prostate cancer should it recur (Heidenreich et al. 76). 
Another treatment for prostate cancer is Androgen Deprivation Therapy (also referred to as 
hormone therapy). The growth of most prostate cancer cells is dependent on androgens (sex 
hormones), most often testosterone or dihydrotestosterone (Miyamoto et al. 332). To treat 
prostate cancer, hormone deprivation therapy aims to stop the production of testosterone. This 
is achieved by either pharmaceutically or surgically castrating the patient, or stopping the body’s 
natural production of androgens (Miyamoto et al. 332). Androgen deprivation therapy is not a 
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curative treatment, it is used to slow the disease progression and extend patient life (Miyamoto 
et al. 344). This therapy is often used with patients whose initial treatment of RALP or EBRT has 
not been successful, resulting in the disease spreading to other areas of the body (Heidenreich et 
al. 76). 
Introduction 
Patients who undergo treatment for prostate cancer find it difficult to maintain a high quality 
of life due to impaired urinary and sexual function, since nerves that supply the urethra and 
penis are contained in neurovascular bundles that run posterior-laterally along the prostate 
(Walsh et al. 473). Surgical removal or radiation of the prostate can damage these nerves and 
have a severe impact on urinary and sexual function of patients after treatment, which can lead 
to a lower quality of life (Walsh et al. 473). Quality of life for patients being treated for prostate 
cancer is a major factor in the decision of which treatment to choose. Poorer quality of life due to 
incontinence and erectile dysfunction can lead to depression, poorer quality of sleep, and lower 
levels of overall of health (Coyne et al. 1388).  
For cancer that is localized to the prostate, both Robot Assisted Laparoscopic Prostatectomy 
(RALP) and External Beam Radiation Therapy (EBRT) are considered acceptable treatments 
(Schreiber et al. 21). Patient input is essential in the treatment decision, thus randomized-
control studies are difficult to perform to determine which treatment has better quality of life 
outcomes. Researchers have heavily relied on retrospective studies to assess the benefits of one 
treatment versus another, but these studies often yield no clear distinction. EBRT and RALP are 
both associated with a decline in Health Related Quality of Life (HRQOL) directly after 
treatment, but thus far there is no clear indication as to which is the superior treatments in 
terms of the recovery of urinary and sexual function (Miller et al. 2775; Frank et al. 2151). Many 
studies that investigate this were performed prior to 2006, when RALP surgical techniques 
became more widespread, and therefore only included comparisons of Radical Retropubic 
Prostatectomy to EBRT. These studies found that patients treated with EBRT had better 
recovery of urinary and sexual function than those treated with RRP (Litwin et al. 2239; Potosky 
et al. 1358). The purpose of this study was to compare recovery of urinary and sexual function 
using information from the Prostate Cancer Health Related Quality of Life (HRQOL) database in 
patients that were treated with RALP or EBRT to determine if EBRT results in better sexual 
and/or urinary function recovery in patients two years after initial treatment compared to 
RALP. The study used the Expanded Prostate Index Composite (EPIC) questionnaire to measure 
the patients’ urinary, bowel, hormonal, and sexual irritation. It was hypothesized that the 
changes in sexual function EPIC scores would indicate better sexual function recovery for 
patients treated with EBRT than RALP, and changes in urinary function EPIC scores would 
indicate better recovery of urinary function in patients treated with RALP than EBRT.  
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Table 1 
Criteria for subject selection of each treatment group 
Table 1 
Criteria for subject selection of each treatment group 
Methods 
Patient Selection 
This study compared External Beam Radiation Therapy (EBRT) to Robot Assisted 
Laparoscopic Prostatectomy (RALP), so patients selected for this study were good candidates for 
both EBRT and RALP at the time of their initial treatment. Almost all patients are good 
candidates for EBRT, but not all qualify for RALP. Therefore, only EBRT patients that were 
specifically noted to also qualify 
for RALP were selected for this 
study (see table 1). Surgical 
guidelines denote that patients 
should live long enough to benefit 
from lack of malignancy. As RALP 
is an invasive procedure, a patient 
should have a life expectancy of 10 
years or more to receive treatment 
(Lepor 182). Although the 
probability that a man 70 years old 
will live 10 more years after 
prostatectomy is about 58% (Lepor 183), Oregon Urology Institute physicians do not 
discriminate treatment based on age and will select RALP if a patient has an estimated ten-year 
life expectancy. Thus, patients were selected for this study if it specified in their charts that they 
were good surgical candidates at the time of their initial treatment consultation. Patients 
selected had a Gleason Score of 6-8, which indicated that they needed initial treatment. Patients 
with a Gleason score of 9-10 are classified in the high-risk category and most often receive 
multiple treatment types such as surgery or radiation with hormone deprivation therapy 
(Fowler, Jr et al. 3221). Multiple treatments could confound the study results, so these patients 
were not included. Selected patients had a TNM score in the range of T1a-T3a, indicating they 
still had organ confined prostate cancer, and were therefore eligible for prostatectomy (Lepor 
183). Patients who were selected for the RALP subject group underwent a form of a nerve 
sparing procedure (Bilateral, Right, Split, etc.) to improve erectile function.  
Data Collection 
Sexual and Urinary Function Data 
Measurements for Sexual and Urinary function have been acquired through the EPIC. EPIC 
questionnaires inquire about the patient’s urinary, bowel, hormonal, and sexual irritation, which 
reflects their urinary, bowel, hormonal, and sexual function (Wei et al. 899). The EPIC 
questionnaires relates the scores (1-5 or 1-4) in a section and calculates a percentage that gives a 
summary of the function for that section. Thus, if the top score is selected by the patient for each 
question in a section such as urinary function, that patient would receive 100 for that section 
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when their EPIC score is calculated. Higher scores represent less irritation and better function. 
The scores recorded for sexual and urinary function were used in this study, and all other 
information was omitted. A packet with this questionnaire is sent out to patients willing to 
participate in the Prostate Cancer Database before their treatment, then quarterly for the first 
year following treatment, and then annually. The two-year time point was chosen to assess 
recovery of urinary and sexual function since improvement in both generally does not occur past 
twenty-four months (Penson et al. 42; Donovan et al. 1429).  
Treatment Related Information 
Many co-variants were included in this study. Smoking status was determined based on 
smoking status at time of treatment. Co-morbidities were recorded from conditions recorded in 
patients’ chart at time of treatment. Race was recorded from self-reported race in patients' 
charts. Use of hormone therapy was determined from listed medications on the patient’s chart. 
Erectile aid use before and at the two-year time point was determined based off medication lists 
and notes made in the patient’s chart. Other information regarding Gleason Score and other 
biopsy information was recorded from the biopsy pathology report, and the TRUS surgical 
report. Surgery related information, such as procedures performed and diagnostics, were 
recorded from the prostatectomy pathology report and the surgical notes.  
Statistical Analysis 
The patients’ clinical presentations were analyzed with Welch’s t-test (two tailed t-test with 
unequal variance). Demographic characteristics, which were included as possible confounding 
variables, were analyzed with Fisher’s exact test. A Wilcoxon rank-sum test was used to compare 
baseline BMI of patients in each treatment group, as there were not normal distributions. 
General Linear Models (GLM) were used to assess significant differences between treatment 
groups, and identify if any variables were confounding the relationship between treatment 
groups and EPIC scores for urinary and sexual function. 
Table 2 shows the clinical presentations of each treatment group. The patients in both 
treatment groups were largely similar. One statistically significant difference was the TNM Stage 
between the two treatment groups. The RALP treatment group had a slightly higher average 
TNM staging of T2b than the EBRT group’s T2a.  
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Patient Demographics 
 
 
  
EBRT    RALP   
Average Mode   Average Mode   
Age at start of 
tx (yr) 
66 
SD: 7 
59 
  
  64 
SD: 6.8 
68 
  
  
    
PSA Level 
(ng/mL) 
5.7 
SD: 3 
5.5 
  
  6.1 
SD: 4.3 
5.5 
  
  
    
Prostate Size 
(mL) 
43 
SD: 15.8 
- 
  39.8 
SD: 20.2 
33 
  
  
    
Gleason Score  
6.4 
SD: 0.5 
6 
  
  6.6 
SD: 0.7 
6 
  
  
    
1st Grade 
3.1 
SD: 0.3 
3 
  
  3.2 
SD: 0.4 
3 
  
  
    
2nd Grade 3.3 3   3.4 3   
Table 2 
Comparison of Clinical Presentations for EBRT and RALP Patients 
*Statistically significant with Welch’s T-test p< .05. 
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SD: 0.5   
  
SD: 0.5   
  
Biopsies (% of 
positive 
samples) 
35.6 
SD: 22.4 
25 
  
  35 
SD: 20.4 
33 
  
  
    
Highest % of 
Cores 
49 
SD: 28.7 
80 
  
  46 
SD: 29.9 
80 
  
  
    
Clinical TNM 
Stage*  t2a t1c 
  
t2b t2c 
  
    
BMI 
29.1 
SD: 4.4 
-   
27.9 
SD: 3.9 
 
25.9 
 
  
 
Fisher’s exact test revealed significant differences in the amount of cardiac disease between 
treatment groups. The EBRT group had more instances of cardiac disease, with 41% of the 
patients with cardiac disease (see table 3). This prevalence of a disease, which influences the 
patient’s overall health, suggests that the EBRT patient group was generally less healthy than 
the RALP group. Fisher’s exact test revealed statistically significant differences in the number of 
patients treated with hormone therapy between groups during the time interval this study 
analyzed. The EBRT group had more patients treated with hormone therapy within the two-year 
interval post initial treatment (16% vs. 1%) (see table 3). As there is decreased libido, as well as 
other symptoms, related to the use of hormone therapy, the patient’s sexual function EPIC 
scores could be affected by this treatment. The demographic categories of race and use of 
erectile aid were not included in the GLM analysis due to an unacceptable amount of missing 
data.  
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 Number of Patients (%)  
 EBRT RALP  
Patients Included 
Total number of patients 32 104  
Lost to follow up 0 (0%) 7 (6.7%)  
Deceased 0 (0%) 2 (2%)  
Radiation after initial tx 0 (0%) 10 (10%)  
Pt w/ family history of 
prostate cancer 11 (34%) 32 (31%)  
Comorbidities** 
No comorbidities 12 (38%) 94 (90%)  
Cardiac disease** 13 (41%) 2 (2%)  
Hypertension 1 (3%) 5 (5%)  
Arterial disease 0 (0%) 1 (1%)  
Table 3 
Comparison of Covariates in Treatment Patient Population 
*Indicates statistically significant differences between the treatment groups p < .05 ** Indicates 
statistical significant differences between treatment groups p < .001    ° Indicates variable not included 
in analysis due to missing data 
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Smoking Status* 
Pt never smoked 12 (38%) 58 (56%)  
Pt current smoker 2 (6%) 1 (1%)  
Pt former smoker 18 (56%) 39 (38%)  
Race° 
Alaskan native 1 (3%) 0 (0%)  
White 23 (72%) 65 (63%)  
Race not reported 8 (25%) 39 (37%)  
Erectile Aid Use°  
No Erectile aid use before tx 6 (19%) 92 (88%)  
Erectile aid use before tx 26 (81%) 11 (11%)  
Erectile aid use not reported 
before tx 0 (0%) 1 (.01%)  
No Erectile aid after tx 22 (69%) 32 (30%)  
Erectile aid use after tx  9 (28%) 50 (48%)  
Erectile aid use not reported 
after tx 1 (3%) 22 (21%)  
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Hormone Therapy*  
Received hormone therapy 5 (16%) 1 (1%)  
No hormone therapy 27 (84%) 103 (99%)  
Statistical Tests 
Figure 5 shows the distribution of urinary change scores for EBRT and RALP. The unadjusted 
GLM model illustrated in Table 4 had an overall F value of 0.52. This F value is not less than 
0.05, suggesting that this model is not a successful fit, so an adjusted model was run.  
 
Fig 5. Distribution of Urinary EPIC Score Change  
In this figure, zero denotes baseline. As two-year scores were subtracted from pre-treatment 
scores, negative scores indicate improvement from initial urinary function and positive scores 
represent a worsening from initial urinary function. 
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Table 4 
Reported Values from the Urinary Function Unadjusted GLM Model 
      
  Unadjusted GLM Model   
      
Mean  R2  Pr  > F  
-1.22  0.003  0.52  
      
  Estimate  Pr > |t|  
      
Intercep
t  -1.79  0.35  
EBRT  2.71  0.52  
RALP  0.00    
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Table 5 shows the reported values of the fully adjusted GLM model that included possible 
confounding variables. The variables that were found to confound the association (to have an 
effect on change in urinary EPIC score independent of treatment group) of study variables were 
cardiac disease, arterial disease, age, body mass index (BMI), smoking, hypertension, and 
hormone treatment. None of these variables were found to modify the association (act in 
association with treatment group to affect urinary EPIC score) of study variables. The F-value 
for the fully adjusted GLM model was 0.0076, indicating a good fitting model (see table 5). The 
R2 value generated by this analysis was 0.18. This indicates that the treatment groups and all of 
the confounding variables explain 18% of the variation in urinary change for all the patients 
included in this analysis (see table 5).  EBRT had 4.45 greater increase in urinary change score 
than RALP, indicating a worsening in urinary function from baseline (as positive values 
represent a worsening in function) (see table 5). This association is not statistically significant 
with a p-value of 0.40. Thus, no statistically significant change was detected between urinary 
score change for EBRT and RALP. The mean value of all patients included in the GLM 
procedure was -0.81 (see table 5). As this value is negative, it shows that there was a general 
improvement of urinary function in men treated for prostate cancer with either treatment.  
 
      
  Adjusted GLM Model    
      
Mean  R^2  Pr > F  
-0.81  0.18  0.0076  
      
  Estimate  Pr > |t|  
      
Table 5 
Reported Values from the Urinary Function Fully Adjusted GLM Model 
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Figure 6 shows the unadjusted GLM model of change in sexual function from pre-treatment 
to two years post treatment. The F-value reported in Table 6 for this model was 0.012 indicating 
the model was a good fit. The R2 value is 0.05, indicating that 5% of the variation in change 
sexual function from pre-treatment to 2 years is explained by type of treatment (see table 6). 
The difference in sexual function for patients undergoing EBRT was -11.9, which was statistically 
different (p = 0.01) (see table 6). As negative numbers represent an improvement in sexual 
function from baseline, this indicates that EBRT patients had better sexual function than RALP 
patients. 
Intercept  10.19  0.61  
EBRT  4.45  0.41  
RALP  0.00    
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Fig 6. Distribution of Sexual EPIC Score Change   
In this figure, 0 denotes baseline. As two year scores were subtracted from pre-treatment scores, negative scores indicate 
improvement from initial urinary function and positive scores represent a worsening from initial urinary function. 
*Indicates a statistically significant difference (p < 0.05) 
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Table 6 
Reported Values from Sexual Function GLM Unadjusted Model 
      
  Unadjusted GLM Model   
      
Mean  R^2  Pr > F  
15.94  0.052  0.012  
      
  Estimate  Pr > |t|  
      
Intercep
t  18.34  <.0001  
EBRT  -11.88  0.012  
RALP  0.00    
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Table 7 
Reported Values from Sexual Function Fully Adjusted GLM Model 
      
  Adjusted GLM Model    
      
Mean  R^2  Pr > F  
15.94  0.06  0.028  
      
  Estimate  Pr > |t|  
      
Intercep
t  18.43  <.0001  
EBRT  -10.42  0.036  
RALP  0.00    
      The fully adjusted GLM procedure included hormone treatment in the analysis, as it 
was found to confound the relationship between treatment group and change in EPIC 
sexual function score. However, it was found that hormone treatment did not modify the 
association (act in conjunction with type of treatment) to affect change in EPIC score. 
The F value for the fully adjusted GLM model shown in Table 7 was 0.028, 
demonstrating a model of good fit. The R2 value was 0.06, which indicates that 
treatment group can explain 6% of the variation in change in sexual function from 
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baseline to two years (see table 7). The difference in change between the EBRT patients 
and the RALP patients was -10.4, which is a statistically significant difference (p = 0.04) 
(see table 7). As negative numbers represent an increase in function, EBRT patients have 
better sexual function than RALP patients.  
Discussion 
This study compared External Beam Radiation Therapy (EBRT) to Robot Assisted 
Laparoscopic Prostatectomy (RALP) in terms of urinary and sexual function change from pre-
treatment. The purpose of this comparison was to determine if either treatment provided better 
outcomes for patients. It was hypothesized that RALP patients would have better improvement 
in urinary function, and EBRT patients would have better improvement in sexual function. 
The study’s results found no significant difference between the treatments for change in 
urinary function at the two-year time point. This indicates that neither treatment is superior at 
preserving urinary function. The mean value of all of the patients included in the analysis of 
urinary function was negative. This indicates that, in general, all patients who undergo 
treatment for prostate cancer experience improved urinary function from before their initial 
treatment. This study’s finding of no significant difference between urinary function change and 
treatment groups does not coincide with a study performed by Chien in 2017.  This study found 
that urinary function was significantly worse in RALP patients compared to other treatments 
such as EBRT (Chien et al. 520). As there are still few studies that compare RALP to EBRT these 
conflicting findings cannot be reconciled.  
A significant difference was found in the change in sexual function scores between treatment 
groups. The EBRT patients had a difference in change of -10.4 from the RALP patients. As 
negative numbers indicate an improvement in function, EBRT patients’ sexual function 
improved when compared to RALP patients (p = 0.04). This indicates that EBRT is the superior 
treatment in the preservation of sexual function. These findings agree with Chein’s 2017 study 
that found EBRT patients had better sexual function when compared to RALP patients.  
This study has limitations that affect the conclusions that are drawn. As this study was 
performed with self-report EPIC questionnaires, there is the chance that the answers the 
subjects provided are not an accurate representation of their urinary or sexual function. There 
was also a much smaller sample size of EBRT patients compared to RALP patients, largely due 
to extensive missing data in pre-treatment scores for patients treated with EBRT. The missing 
data likely results from differences in EPIC packet distribution across sites where treatment is 
being delivered. The Research Department is located at the main campus, the same site where 
RALP patients receive treatment. This allows more effective pre-treatment packet delivery to 
RALP patients when compared to patients being treated at the satellite EBRT clinic, where the 
Research Department has much less direct influence over packet delivery. This study also relied 
heavily on data in patient charts for assessment of cofounding variables. If these charts were not 
updated or did not contain the information gathered by this study, the effect of these cofounding 
variables determined in this study could be inaccurate. As was mentioned, there was extensive 
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missing data for two variables: erectile aid use and race. A study that was designed to collect this 
information in a more reliable way, rather than relying on information included in a patient’s 
chart, would be able to assess confounding variables to a more accurate degree. The diversity of 
patients is also a limitation. The racial demographic of subjects included in this study was 
comprised almost entirely of white men, which makes it difficult for the findings to be 
representative of the entire population of men with prostate cancer. In addition to race, this 
study was unable to include socioeconomic status and other influences such as access to health 
care facilities in the analysis. This severely limits the implications of the study’s findings when 
applied to larger populations, since these are important indicators in health outcomes and could 
have confounded the results of this study. A study that examined a group of more diverse 
subjects, and included other determinants of health outcomes such as socioeconomic status 
would be able to draw more extensive conclusions.  
This is one of the first studies that compares RALP to other treatments. More studies that 
compare RALP to other treatments are needed to assess which treatment will best suit patient 
needs. As use of erectile aids was not able to be included in this analysis due to extensive 
missing data, studies that analyze the role of erectile aid use in sexual function change after 
prostate cancer treatment should be conducted to evaluate how erectile aid use affects the 
change in sexual function in relation to different treatment types. 
Conclusion 
Health related quality of life in regards to urinary and sexual function varies by treatment. 
This study supports that EBRT is a better therapy for preserving sexual function, and 
demonstrates that either treatment will preserve urinary function to a similar degree. These 
findings will supplement the growing information about how different prostate cancer 
treatments will affect a patient’s quality of life after treatment, thus providing the option for 
treatments to be specified to a patient’s needs. The more patients can be informed about their 
health care choices the more they can understand the implications and consequences of their 
choices to make a decision about treatment that is best for them. Studies such as this that 
compare RALP and EBRT within a larger and more diverse population are needed to support 
and add to this study’s finding, thereby achieving a greater understanding of how these 
treatments affect quality of life after treatment. 
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